Evolent HealthEVH
Recorded

Evolent Health 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration44 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the Evolent earnings conference call for the third quarter ended September 30, 2026. As a reminder, this conference call is being recorded. Your hosts for the call today from Evolent are Seth Blackley, Chief Executive Officer, and Mario Ramos, Chief Financial Officer. An audio playback of the conference call will be archived and available later this evening and for 90 days after this call via the webcast on the company's website in the section titled Investor Relations. This conference call will contain forward-looking statements under the U.S. federal laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations.

Operator

A description of some of the risks and uncertainties can be found in the company's reports that are filed with the Securities and Exchange Commission, including cautionary statements included in our current and periodic filings. For additional information on the company's results and outlook, please refer to our third quarter press release issued earlier today. Finally, as a reminder, reconciliations of non-GAAP measures discussed during today's call to the most direct comparable GAAP measures are available in the summary presentation available in the Investor Relations section of our website or in the company's press release issued today and posted on the Investor Relations website, ir.evolent.com, and the Form 8-K filed by the company with the SEC earlier today. In addition to reconciliations, we provide details on the numbers and operating metrics for the quarter in both our press release and supplemental investor presentation.

Operator

I will now turn the call over to Evolent CEO, Seth Blackley.

Seth BlackleyCEO

You may now begin. Good morning, and thank you for joining us.

Seth BlackleyCEO

Today, we reported third quarter results that we believe reflect strong continued progress against the priorities we laid out at the beginning of the year. We grew our Performance Suite business, improved our care margins, and stayed disciplined on operating expenses, all while continuing to innovate at the core of our business. For the quarter, Evolent reported total revenue of $725 million, up 11% versus Q2, and Adjusted EBITDA of $34 million, up approximately 22% sequentially. Our medical expense ratio, or MER, was 93%, compared with 95% in the second quarter. The improvement reflects favorable in-year claims development and contractual adjustments. Mario will provide more details on those drivers in a few moments.

Seth BlackleyCEO

Based on our results through the first nine months and our current view of the fourth quarter, we are reiterating our full-year revenue guidance of $2.6 billion-$2.7 billion and raising our Adjusted EBITDA guidance to $130 million-$135 million. Before turning it over to Mario, I want to talk you through four topics. One, the strength of our customer relationships and the related growth. Two, updates from our 2026 Performance Suite launches. Three, how we are both broadening our product footprint and accelerating our AI innovation. And fourth, our balance sheet. Let's start with the initial topic of customer relationships and growth. As we've discussed on previous calls, renewals and expansions are at the heart of our growth story. I'd like to share several proof points of that today. First, we renewed our largest Surgical Management customer contract for an additional four years.

Seth BlackleyCEO

You will recall, Surgical Management is the IPG business we acquired in 2022. We view this as more than a renewal. It's a longstanding partner committing to a multi-year deal, demonstrating that our model works and that they want us at their side managing musculoskeletal and cardiovascular care for the long run. Second, an existing client signed an agreement to expand their oncology offering, covering several additional states and approximately 1 million commercial lives, with go-live expected January 1, 2027. This is our first expansion with this client, and we believe it demonstrates the trust they've placed in us, but also something more strategically important. It's significant to note that this expansion will also include Member Navigation across all existing and new lives, meaning we're not just growing with the client, we are broadening the footprint by adding our member-facing solution.

Seth BlackleyCEO

This is exactly the kind of product breadth expansion that defines our next phase of growth, taking a client under contract with one solution and giving them a reason to trust us with additional solutions. Third, we're expanding our relationship with a national payer in the Specialty Technology and Services product, adding 11 additional states effective November 1, 2026. These 11 additional states add to our existing footprint of 39, making Evolent this client's nationwide provider across our full suite of oncology specialties. This client now represents approximately 7 million lives, all of which are managed by Evolent. Alongside that expansion, we rolled out a new cancer care model in partnership with the American Oncology Network, or AON, that aims to reduce the prior authorization burden for providers, designed to improve quality, timeliness, and affordability for patients.

Seth BlackleyCEO

This model has been initially rolled out across clinics in eight states, and it's a blueprint for where we believe oncology care is headed, which is less friction, more trust, and better outcomes. Taken together, we believe these wins tell a consistent story. Our customers are not just staying with us, they're asking us to do more for them, which gives us a durable foundation to keep expanding our products and deepening the value we deliver over time. Next, as in quarters past, I want to update you on our 2026 Performance Suite launches with Aetna and Highmark. As of Q3, we are now beginning to see favorable claims run out relative to our initial reserves, contributing to the MER favorability we're seeing this quarter, and reflecting our successful implementations. Mario will speak to this in more detail shortly.

Seth BlackleyCEO

On Highmark specifically, we continue to make strong progress since our launch in May, and while it's still early in the partnership, we believe we're ahead of plan with all leading indicators tracking better than budget. Let me now turn to the third update, which is product expansion and innovation. In terms of our broader strategy, our growth trajectory rests on two pillars that I remain excited about. The first one is continuing to push the boundaries of our core specialty offering, especially in oncology, which remains the largest and most important growth driver for our business, and we believe will represent over 70% of Evolent's 2027 revenue.

Seth BlackleyCEO

Health plans are navigating a specialty in oncology where effective treatment can mean choosing correctly among a wide range, and growing range, of evidence-based regimens for a single cancer type, which is exactly why we believe the clinical depth we bring matters, and why we keep investing in it. As I mentioned earlier, we've expanded the oncology solutions as it relates to our Member Navigation products. In addition, we're embedding our clinical pathways directly into the EMRs of leading oncology groups in our network. We expect both of those innovations to continue to expand over the coming years. Our second pillar is AI, which is relevant for all of our specialties, oncology of course, but even more so in high-volume areas like imaging, musculoskeletal care, and cardiovascular care.

Seth BlackleyCEO

I want to spend a moment updating you on our progress and share why we believe we are now the market leader in AI for specialty reviews. We have been building our foundation in AI for several years, beginning with our acquisition of Machinify Auth, an AI-native utilization management technology in 2024. We have since integrated and scaled that platform into what we now call AuthIntelligence. We took that platform from initial test markets to deployment over the past year, and we believe the initial results are incredibly strong. Let me step back and remind you of the purpose of this AuthIntelligence platform. First, according to medical literature, approximately 20% of care across any given specialty is the wrong or inappropriate care, defined as unnecessary, low value, or dangerous to the member.

Seth BlackleyCEO

It creates cost and increased premiums and co-pays for members, and more importantly, may risk their health and safety. At Evolent, we're focused on identifying which 20% of cases are the wrong or inappropriate care, and which 80% represent appropriate care. Our AuthIntelligence platform uses our unique clinical pathways and over 15 years of proprietary data to identify in real time which is the 20 and which is the 80. The result of any false positive or false negative means touching cases with manual review that are in the 80 that could have been auto-authorized at low cost to the AI provider, or missing cases that are in the 20 that need more nuanced human intervention.

Seth BlackleyCEO

We believe that with AuthIntelligence in place, we are able to correctly identify both the 80 and the 20, improving the process for patients and providers while maintaining the clinical value and clinical safety for our health plan partners. Because getting this model right requires large amounts of unique data, and because the model will continue to learn in a self-reinforcing loop, we believe this capability provides an important moat for Evolent in the years to come. Over the last several months, AuthIntelligence has moved well beyond pilot phases, and today, where deployed, AuthIntelligence evaluates approximately half of all our prior authorization volume that previously required manual clinical review. Today, AuthIntelligence is touching approximately 1 million cases per year. We expect that more than 80% of all manual auths, or approximately 2 million cases, to run through our AuthIntelligence platform by the end of 2027.

Seth BlackleyCEO

Importantly, at customers and case types where AuthIntelligence is deployed, we have seen auto-approval rates improve by as much as 20 percentage points while maintaining clinical value. Said another way, we have seen auto-authorization rates jump from 60% to 80% in certain instances. It is important to note that just a 10% improvement in our auto-authorization rate translates to a reduction in approximately 600,000 manual touches per year, driving meaningful operating cost savings for Evolent. While we share some of those savings back with our clients in various forms, we believe our AI platform will be a source of margin expansion, and given the differentiation of our solution, particularly in its ability to drive efficiency while maintaining clinical value, will also be a driver of market share expansion and revenue growth in the time ahead.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day